Physician profile
Michelle Stas
NPI 1962473843
$3,091.58
in general payments reported to CMS, 2019-2025
22 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $52.27 · 2021: $284 · 2022: $579 · 2023: $539 · 2024: $524 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $660.22 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $370.42 | 2022-2025 | |
| Astellas Pharma US INC | $329.26 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $293.23 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Kci USA, INC. | $181.82 | 2019 | |
| Aspira Women'S Health INC | $170.35 | 2021-2024 | Ova1 |
| Organon LLC | $167.69 | 2021-2024 | Nuvaring, Nexplanon |
| Therapeuticsmd, INC. | $135.15 | 2019-2022 | |
| Millicent US INC | $121.38 | 2023-2024 | Femring, Intrarosa |
| Exact Sciences Corporation | $113.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Coopersurgical, INC. | $113.52 | 2019-2024 | Paragard T 380a, Endosee, Paragard T 380a |
| Pfizer INC. | $104.12 | 2019-2024 | |
| Shield Therapeutics INC | $52.96 | 2025 | |
| Exeltis, USA INC. | $50.25 | 2024-2025 | Slynd |
| Sumitomo Pharma America, INC. | $48.10 | 2024-2025 | Myfembree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $44.96 | 2019 | |
| Seqirus USA INC | $37.21 | 2024-2025 | Flucelvax |
| Evofem Biosciences, INC. | $34.87 | 2021-2022 | |
| Hologic Sales and Service, LLC | $26.19 | 2025 | Aptima |
| Ibsa Pharma INC. | $23.90 | 2023 | Tirosint, Licart |
| Minerva Surgical, INC | $12.04 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Stas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.